We appreciate the interest of Jordan and Birkenfeld ([@B1]) on our recent publication in *Diabetes* ([@B2]). In this article, we showed that intravenous infusion of B-type natriuretic peptide (BNP) decreases hunger and increases satiety in healthy men and lowers circulating concentrations of ghrelin and acylated ghrelin in the absence of changes in other appetite-regulating hormones ([@B2]).

Jordan and Birkenfeld discuss the impact of elevated BNP concentrations on food intake and potential mechanisms underlying the anorectic effects of BNP ([@B1]). We have clearly written in both the abstract and the article that our study was performed in fasted individuals, and we neither studied nor commented on BNP effects on food intake ([@B2]). The anorectic and ghrelin-lowering effects of BNP during fasting were observed in the absence of changes in both plasma glucose (*P* = 0.127; repeated-measures ANOVA, time × treatment) and circulating free fatty acid concentrations (*P* = 0.563; repeated-measures ANOVA, time × treatment). Furthermore, in a previous interventional study in men we also excluded direct BNP effects on β-cell function and insulin sensitivity ([@B3],[@B4]). All our BNP interventions in men were performed in supine position in order to avoid changes in blood pressure and subsequent counterregulatory mechanisms that might indirectly affect study outcomes ([@B2],[@B3]).

In summary, anorectic BNP effects reported in men while fasting cannot be related to changes in nutrients and insulin, and the postulation of a heart-gut-brain communication is supported by the data presented in the article ([@B2]). The link between BNP, ghrelin, and appetite might represent an important physiological axis participating in the complex interrelated central and peripheral mechanisms regulating appetite in humans.
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